If they have something, welcome to humanity. C’mon. Maybe I’ll buy your shares too.”
It’s funny because I keep telling my friend who first got me into Cytodyn that soon we’re going to need to start looking for the next Cytodyn once this fully takes off. It could very well be that the next great Cytodyn-like investment opportunity comes from the company who sees the success of Leronlimab across indications and targets the same receptors.
Or figures out how to improve upon what Leronlimab does.
Advair and Spiriva both did billions for COPD. Cialis and Viagra for stiffies. Allegra, Zyrtec, and Claritin/Clarinex for allergies. There will absolutely be some challenges to the champ once Leronlimab displays the golden gloves.
Thanks for your post. It got me thinking and I’m definitely going to closely watch any non-BP that gets in the CCR5 game.